Psoriasis Clinical Trial
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
Participant is pregnant and ≤10 weeks gestation at the time of enrollment
Participant must have been on stable, maintenance dose certolizumab pegol (CZP) treatment for at least 12 weeks independent of and prior to being enrolled in this study, for an approved indication in accordance with her treating physician
Participant expects to continue CZP therapy throughout pregnancy and for at least 12 weeks postpartum
Participant has a negative interferon gamma release assay (IGRA) or tuberculin skin test (TST) within the prior 6 months, and there has been no change in the study participant's clinical status, or social, family, or travel history. Participants with documented Bacillus Calmette-Guérin (BCG) vaccine and at low risk for tuberculosis (TB) may enroll without having a TB test performed
Participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study
Participant is not permitted to enroll into the study if she meets any of the following TB exclusion criteria:
Known active TB disease
History of active TB involving any organ system
Latent TB infection
High risk of acquiring TB infection
Current nontuberculous mycobacterial (NTM) infection or history of NTM infection (unless proven to be fully recovered)
Study participant is taking a prohibited medication or has taken a prohibited medication
Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study
Study participant has any clinically significant pregnancy-related clinical or test abnormality, as judged by the investigator
Study participant had a positive or indeterminate interferon gamma release assay (IGRA) or tuberculin skin test (TST) at Screening. In case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the study participant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Minneapolis Minnesota, 55455, United States
Durham North Carolina, 27710, United States
Oklahoma City Oklahoma, 73104, United States
Paris , , France
Freiburg , , Germany
Hamburg , , Germany
Barcelona , , Spain
Bern , , Switzerland
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.